Lilly to acquire ImClone for $6.5bn
Eli Lilly has agreed to acquire ImClone for $6.5bn and in doing so appears to have snatched the biotech away from Bristol-Myers Squibb (BMS), which first tabled a bid back in July.
New software to ease regulatory document burden
Good Products and Adlib Software have teamed up to create a streamlined and compliant regulatory document management system for the pharmaceutical industry.
Handheld device for validating raw materials
Ahura Scientific has launched an updated version of its TruScan handheld instrument, which allows for raw materials to be quickly verified.
Teva Kowa JV to target Japanese generics market
Teva and Kowa have set their sights on Japan’s $4.6bn (€3.1bn) generics market with their development and manufacturing joint venture Teva-Kowa Pharma.
Zentiva board accepts Sanofi’s revised €1.8bn offer
Sanofi-Aventis’ €1.8bn ($2.6bn) offer for Czech generics firm Zentiva has been unanimously accepted by the latter firm’s board after four months of wrangling that has seen the bid increase by 9.5 per cent.
IPEC China’s chairman sets out next steps
Exclusive interview with IPEC China chairman Nevin Cheng
IPEC China must become a “harmonisation bridge between China and other countries,” according to Colorcon’s Nevin Cheng who was recently elected chairman of the new organisation.
Drugmakers within EC's REACH, says SAFC
Despite a decade-long build up, drugmakers are yet to wake up to the “no data, no market” mantra of the EC’s REACH legislation, according to SAFC’s marketing director Amanda Halford.
Israeli court rules against “disingenuous” Taro
The Tel-Aviv District Court has found in favour of Sun Pharmaceuticals in its long running struggle to acquire Israeli drug and pharmaceutical ingredient maker Taro Pharmaceutical Industries.
Conformia’s platform combined with IBM system
Conformia says that the integration of its SOA data platform into IBM’s system will provide drugmakers with robust management architecture for the entire lifecycle of a product.
USP opens its first site in Brazil
The US Pharmacopeia (USP) has continued to expand its global reach by opening a site in São Paulo, Brazil; its first in Latin America.
Genentech rejects Roche but leaves door ajar
Genentech’s special advisory committee has rejected Roche’s $44bn offer for the biotech believing that it “substantially undervalues” the company.
Pfizer to lose top spot by 2014
A new report predicts that current global sales leader Pfizer will relinquish its position by 2014 leaving European pharmaceutical producers like Roche and Sanofi-Aventis free to vie for the top spot.
APC parent to be bought by Otsuka Chemical
US protein manufacture and development services provider American Peptide Company (APC) says that its parent company, Ito Life Sciences (ILS), is to be acquired by fellow Japanese firm Otsuka Chemical.
Anti-counterfeiting news in brief
in-PharmaTechnologist.com's round-up of developments in the fight against counterfeiting, including Movianto’s ‘DNA’ coding, e-pedigree packaging machinery and a new handheld device.
West African conference to eradicate counterfeits
West African states are meeting to devise a plan for cleaning up their tarnished reputations with regards to the flow of counterfeit pharmaceuticals in the region.